208 related articles for article (PubMed ID: 19461510)
21. Low-grade serous ovarian cancer: A review.
Kaldawy A; Segev Y; Lavie O; Auslender R; Sopik V; Narod SA
Gynecol Oncol; 2016 Nov; 143(2):433-438. PubMed ID: 27581327
[TBL] [Abstract][Full Text] [Related]
22. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
23. Low-grade serous carcinoma of the ovary displaying a macropapillary pattern of invasion.
Yemelyanova A; Mao TL; Nakayama N; Shih IeM; Kurman RJ
Am J Surg Pathol; 2008 Dec; 32(12):1800-6. PubMed ID: 18779727
[TBL] [Abstract][Full Text] [Related]
24. BRAF mutation is rare in advanced-stage low-grade ovarian serous carcinomas.
Wong KK; Tsang YT; Deavers MT; Mok SC; Zu Z; Sun C; Malpica A; Wolf JK; Lu KH; Gershenson DM
Am J Pathol; 2010 Oct; 177(4):1611-7. PubMed ID: 20802181
[TBL] [Abstract][Full Text] [Related]
25. Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract][Full Text] [Related]
26. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
[TBL] [Abstract][Full Text] [Related]
27. Clinicopathologic, Immunohistochemical, and Molecular Characteristics of Ovarian Serous Carcinoma With Mixed Morphologic Features of High-grade and Low-grade Serous Carcinoma.
Zarei S; Wang Y; Jenkins SM; Voss JS; Kerr SE; Bell DA
Am J Surg Pathol; 2020 Mar; 44(3):316-328. PubMed ID: 31876585
[TBL] [Abstract][Full Text] [Related]
28. Loss of 1p36.33 Frequent in Low-Grade Serous Ovarian Cancer.
Van Nieuwenhuysen E; Busschaert P; Laenen A; Moerman P; Han SN; Neven P; Lambrechts D; Vergote I
Neoplasia; 2019 Jun; 21(6):582-590. PubMed ID: 31054497
[TBL] [Abstract][Full Text] [Related]
29. Molecular genetic analysis of ovarian serous cystadenomas.
Cheng EJ; Kurman RJ; Wang M; Oldt R; Wang BG; Berman DM; Shih IeM
Lab Invest; 2004 Jun; 84(6):778-84. PubMed ID: 15077125
[TBL] [Abstract][Full Text] [Related]
30. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
Sieben NL; Macropoulos P; Roemen GM; Kolkman-Uljee SM; Jan Fleuren G; Houmadi R; Diss T; Warren B; Al Adnani M; De Goeij AP; Krausz T; Flanagan AM
J Pathol; 2004 Mar; 202(3):336-40. PubMed ID: 14991899
[TBL] [Abstract][Full Text] [Related]
31. KRAS, BRAF genotyping reveals genetic heterogeneity of ovarian borderline tumors and associated implants.
Heublein S; Grasse K; Hessel H; Burges A; Lenhard M; Engel J; Kirchner T; Jeschke U; Mayr D
BMC Cancer; 2013 Oct; 13():483. PubMed ID: 24139521
[TBL] [Abstract][Full Text] [Related]
32. KRAS/BRAF Analysis in Ovarian Low-Grade Serous Carcinoma Having Synchronous All Pathological Precursor Regions.
Nakamura K; Nakayama K; Ishibashi T; Ishikawa N; Ishikawa M; Katagiri H; Minamoto T; Sato E; Sanuki K; Yamashita H; Iida K; Sultana R; Kyo S
Int J Mol Sci; 2016 Apr; 17(5):. PubMed ID: 27128903
[TBL] [Abstract][Full Text] [Related]
33. The molecular pathology of ovarian serous borderline tumors.
Malpica A; Wong KK
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
[TBL] [Abstract][Full Text] [Related]
34. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
Mayr D; Hirschmann A; Löhrs U; Diebold J
Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
[TBL] [Abstract][Full Text] [Related]
35. Characterization of TP53-wildtype tubo-ovarian high-grade serous carcinomas: rare exceptions to the binary classification of ovarian serous carcinoma.
Chui MH; Momeni Boroujeni A; Mandelker D; Ladanyi M; Soslow RA
Mod Pathol; 2021 Feb; 34(2):490-501. PubMed ID: 32801341
[TBL] [Abstract][Full Text] [Related]
36. Biomolecular pathogenesis of borderline ovarian tumors: focusing target discovery through proteogenomics.
Vergara D; Tinelli A; Martignago R; Malvasi A; Chiuri VE; Leo G
Curr Cancer Drug Targets; 2010 Feb; 10(1):107-16. PubMed ID: 20088785
[TBL] [Abstract][Full Text] [Related]
37. Amplicon profiles in ovarian serous carcinomas.
Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
[TBL] [Abstract][Full Text] [Related]
38. The status of epidermal growth factor receptor in borderline ovarian tumours.
Showeil R; Romano C; Valganon M; Lambros M; Trivedi P; Van Noorden S; Sriraksa R; El-Kaffash D; El-Etreby N; Natrajan R; Foroni L; Osborne R; El-Bahrawy M
Oncotarget; 2016 Mar; 7(9):10568-77. PubMed ID: 26870997
[TBL] [Abstract][Full Text] [Related]
39. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
40. BRAF
Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]